Artelo Biosciences, Inc.
ARTL
$9.35
-$0.18-1.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 54.66% | -8.04% | 19.71% | -15.45% | -19.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.40% | -8.11% | 17.65% | -54.28% | 40.81% |
| Operating Income | -25.40% | 8.11% | -17.65% | 54.28% | -40.81% |
| Income Before Tax | -32.39% | 4.47% | -22.94% | 53.78% | -52.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.39% | 4.47% | -22.94% | 53.78% | -52.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.39% | 4.47% | -22.94% | 53.78% | -52.16% |
| EBIT | -25.40% | 8.11% | -17.65% | 54.28% | -40.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -24.09% | 6.92% | -20.14% | 57.77% | -15.39% |
| Normalized Basic EPS | -20.18% | 10.73% | -14.98% | 58.24% | -6.78% |
| EPS Diluted | -24.09% | 6.92% | -20.14% | 57.77% | -15.39% |
| Normalized Diluted EPS | -20.18% | 10.73% | -14.98% | 58.24% | -6.78% |
| Average Basic Shares Outstanding | 6.69% | 2.63% | 2.33% | 9.46% | -83.85% |
| Average Diluted Shares Outstanding | 6.69% | 2.63% | 2.33% | 9.46% | -83.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |